QCG
SAGE

Quadrant Capital Group’s Sage Therapeutics SAGE Stock Holding History

Quadrant Capital Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,859
Closed -$38.6K – 2363
2025
Q1 		$38.6K Buy
4,859
+2,840
+141% +$20.8K ﹤0.01% 1803
2024
Q4 		$11K Buy
2,019
+899
+80% +$5.5K ﹤0.01% 2096
2024
Q3 		$8.09K Buy
1,120
+784
+233% +$7.18K ﹤0.01% 2203
2024
Q2 		$3.65K Buy
+336
New +$4.3K ﹤0.01% 2371
2023
Q4 		– Sell
-689
Closed -$14.2K – 2769
2023
Q3 		$14.2K Buy
689
+647
+1,540% +$18.7K ﹤0.01% 1852
2023
Q2 		$1.98K Sell
42
-20
-32% -$995 ﹤0.01% 2420
2023
Q1 		$2.6K Buy
62
+20
+48% +$860 ﹤0.01% 2379
2022
Q4 		$1.6K Sell
42
-25
-37% -$955 ﹤0.01% 2469
2022
Q3 		$3K Hold
67
– – ﹤0.01% 2296
2022
Q2 		$2K Buy
67
+42
+168% +$1.41K ﹤0.01% 2271
2022
Q1 		$1K Sell
25
-34
-58% -$1.28K ﹤0.01% 2377
2021
Q4 		$3K Buy
59
+31
+111% +$1.3K ﹤0.01% 2059
2021
Q3 		$1K Sell
28
-32
-53% -$1.47K ﹤0.01% 2380
2021
Q2 		$3K Sell
60
-9
-13% -$636 ﹤0.01% 2032
2021
Q1 		$5K Sell
69
-12
-15% -$984 ﹤0.01% 1802
2020
Q4 		$7K Buy
81
+15
+23% +$1.11K ﹤0.01% 1589
2020
Q3 		$4K Buy
66
+41
+164% +$2.08K ﹤0.01% 1652
2020
Q2 		$1K Sell
25
-85
-77% -$3.08K ﹤0.01% 2118
2020
Q1 		$3K Buy
110
+103
+1,471% +$5.96K ﹤0.01% 1808
2019
Q4 		$0 Sell
7
-169
-96% -$20.8K ﹤0.01% 2479
2019
Q3 		$23K Sell
176
-172
-49% -$28.8K ﹤0.01% 1554
2019
Q2 		$62K Hold
348
– – 0.01% 1115
2019
Q1 		$53K Buy
348
+341
+4,871% +$49.4K 0.01% 1191
2018
Q4 		$0 Buy
+7
New +$801 ﹤0.01% 2279

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Quadrant Capital Group's SAGE Position: Q2 2025 in Review

Quadrant Capital Group sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 4,859 shares — an estimated $38.6K sold.

Quadrant Capital Group first reported a position in SAGE in Q4 2018 and held it in 24 quarters. The position peaked at $62K in Q2 2019. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Quadrant Capital Group reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 4,859 Sage Therapeutics shares in Q2 2025, an estimated $38.6K.
  • Quadrant Capital Group first reported a position in Sage Therapeutics in Q4 2018 and held it in 24 quarters.
  • Quadrant Capital Group's Sage Therapeutics position peaked at $62K in Q2 2019.
  • 192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.